Lung Cancer | Clinical

Langer Discusses Trials in Multiple Settings for Non–Small Cell Lung Cancer

March 07, 2021

Corey J. Langer, MD, discusses treatment options for a patient with non–small cell lung cancer based on the clinical trial research.

FDA Approves Expanded Indication for Lorlatinib for Frontline ALK+ NSCLC

March 04, 2021

The FDA has expanded the approval for lorlatinib to include an indication for the first-line treatment of patients with ALK-positive non–small cell lung cancer.

Real-World Data to Inform Lung Treatment in the Future

March 03, 2021

Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.

Pembrolizumab Indication for Treatment of Metastatic SCLC Withdrawn

March 02, 2021

Pembrolizumab has been withdrawn from the United States market as a treatment option for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Common and Severe Adverse Events Related to Immunotherapy for Lung Cancer

February 26, 2021

Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.

FDA Approves CDx for Cemiplimab in Non–Small Cell Lung Cancer

February 23, 2021

The FDA has expanded the use of PD-L1 IHC 22C3 pharmDx assay to include the diagnosis of patients with non-small cell lung cancer, announced the developer, Agilent Technologies, Inc.

FDA Approves Cemiplimab in Frontline PD-L1-High Advanced NSCLC

February 22, 2021

The FDA has granted approval to cemiplimab-rwlc, for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK, or ROS1 aberrations.

Atezolizumab Bests Chemotherapy in PD-L1–High Non–Small Cell Lung Cancer

February 22, 2021

Final analysis results from the phase 3 IMpower110 trial show the benefit of atezolizumab over chemotherapy in a non–small cell lung cancer subgroup.

NeoADAURA Trial Launches With Plans to Assess Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

February 18, 2021

n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial

FDA Grants Sotorasib a Priority Review for KRAS G12C+ Advanced NSCLC

February 17, 2021

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.